Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome.
Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome.
复制标题
DOI：
10.1111/j.1365-2982.2011.01776.x
复制
发表时间：
2011-10
影响因子：
3.5
通讯作者：
Tucker J
中科院分区：
文献类型：
--
作者：
Whitehead WE;Palsson OS;Gangarosa L;Turner M;Tucker J
在临床试验中，鲁比前列酮降低了腹痛的严重程度。主要目的是确定鲁比前列酮是否会提高腔内球囊扩张引起的腹痛阈值。次要目的是确定疼痛敏感性的变化是否独立于通过时间的变化而影响临床疼痛。62例肠易激综合征伴便秘（IBS-C）患者参加了一项为期8周的交叉研究。所有受试者完成了14天的基线，结束时进行了疼痛和冲动感觉阈值的恒压器测试。随机选择的一半，然后接受48 μ g/天的鲁比前列酮治疗14天，结束时进行疼痛敏感性测试和通过时间的Sitzmark测试。随后是14天的洗脱期，然后交叉到14天的安慰剂，进行疼痛敏感性和通过时间测试。另一半受试者在鲁比前列酮之前接受安慰剂。所有患者均记录症状日记。与安慰剂相比，服用鲁比前列酮时粪便明显更软（布里斯托粪便评分4.20 vs. 3.44，p<0.001）。然而，疼痛阈值（17.36与17.83 mmHg，鲁比前列酮与安慰剂）和排便急迫性（14.14与14.53 mmHg）不受鲁比前列酮的影响。鲁比前列酮和安慰剂之间的通过时间无显著差异（51.27 vs. 51.81小时），疼痛敏感性和通过时间均不是临床疼痛的显著预测因素。鲁比前列酮对内脏感觉阈值无影响。服用鲁比前列酮时发生的临床疼痛的减少似乎是继发于粪便稠度的变化。
In clinical trials, lubiprostone reduced the severity of abdominal pain. The primary aim was to determine whether lubiprostone raises the threshold for abdominal pain induced by intraluminal balloon distention. A secondary aim was to determine whether changes in pain sensitivity influence clinical pain independently of changes in transit time. Sixty-two patients with irritable bowel syndrome with constipation (IBS-C) participated in an 8-week crossover study. All subjects completed a 14-day baseline ending with a barostat test of pain and urge sensory thresholds. Half, randomly selected, then received 48 ug/day of lubiprostone for 14 days ending with a pain sensitivity test and a Sitzmark test of transit time. This was followed by a 14-day washout and then a crossover to 14 days of placebo with tests of pain sensitivity and transit time. The other half of the subjects received placebo before lubiprostone. All kept symptom diaries. Stools were significantly softer when taking lubiprostone compared to placebo (Bristol Stool scores 4.20 vs. 3.44, p<0.001). However, thresholds for pain (17.36 vs. 17.83 mmHg, lubiprostone vs. placebo) and urgency to defecate (14.14 vs. 14.53 mmHg) were not affected by lubiprostone. Transit time was not significantly different between lubiprostone and placebo (51.27 vs. 51.81 hours), and neither pain sensitivity nor transit time was a significant predictor of clinical pain. Lubiprostone has no effect on visceral sensory thresholds. The reductions in clinical pain that occur while taking lubiprostone appear to be secondary to changes in stool consistency.
登录
查看更多内容
影响因子：
29.4
作者：
Drossman, DA;Toner, BB;Bangdiwala, SI
通讯作者：
Bangdiwala, SI
影响因子：
24.5
作者：
Dorn, Spencer D.;Palsson, Olafur S.;Whitehead, William E.
通讯作者：
Whitehead, William E.
DOI：
10.1152/ajpgi.90558.2008
发表时间：
2009-02-01
影响因子：
4.5
作者：
Sweetser, Seth;Busciglio, Irene A.;Zinsmeister, Alan R.
通讯作者：
Zinsmeister, Alan R.
影响因子：
1.9
作者：
ABRAHAMSSON, H;ANTOV, S;BOSAEUS, I
通讯作者：
BOSAEUS, I
影响因子：
7.6
作者：
Johanson, J. F.;Drossman, D. A.;Ueno, R.
通讯作者：
Ueno, R.